These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6127226)

  • 1. Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies.
    Clark D; Carlsson A; Hjorth S; Svensson K; Engel J; Sanchez D
    Eur J Pharmacol; 1982 Sep; 83(1-2):131-4. PubMed ID: 6127226
    [No Abstract]   [Full Text] [Related]  

  • 2. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
    Martin RS; Secchi RL; Sung E; Lemaire M; Bonhaus DW; Hedley LR; Lowe DA
    Psychopharmacology (Berl); 2003 Jan; 165(2):128-35. PubMed ID: 12404071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat.
    Clark D; Carlsson A; Hjorth S; Engel J; Lindberg P
    Psychopharmacology (Berl); 1983; 81(1):14-7. PubMed ID: 6138790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 7. Behavioral and neurochemical correlates of repeated d-amphetamine administration.
    Segal DS
    Adv Biochem Psychopharmacol; 1975; 13():247-62. PubMed ID: 1171583
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioural actions of neuroleptics are not reduced by hypophysectomy.
    Costall B; Fortune DH; Naylor RJ; Nohria V
    J Pharm Pharmacol; 1982 Sep; 34(9):588-90. PubMed ID: 6127386
    [No Abstract]   [Full Text] [Related]  

  • 9. Behavioral studies on the enantiomers of butaclamol demonstrating absolute optical specificity for neuroleptic activity.
    Voith K; Cummings JR
    Can J Physiol Pharmacol; 1976 Aug; 54(4):551-60. PubMed ID: 10059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of D-amphetamine produced facilitation of avoidance acquisition in rats and performance changes subsequent to drug termination.
    Barrett RJ; Steranka LR
    Life Sci; 1974 Jan; 14(1):163-80. PubMed ID: 4810494
    [No Abstract]   [Full Text] [Related]  

  • 11. Anorexic and behavioural effects of a new imidazo-isoindole derivative (mazindol) in comparison with d-amphetamine in the rat.
    Babbini M; Gaiardi M; Bartoletti M
    Pharmacology; 1977; 15(1):46-56. PubMed ID: 557207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance development to a disruptive effect of beta-phenylethylamine (PEA) on a learned behavior in rats.
    Stoff DM; Moja EA; Jeffery DR; Gillin JC; Wyatt RJ
    Psychopharmacology (Berl); 1979 Nov; 66(2):127-31. PubMed ID: 119255
    [No Abstract]   [Full Text] [Related]  

  • 13. Behavioral effects of cyclobenzaprine.
    Messiha FS; Barnes CD; Hughes MJ; Light KE
    Proc West Pharmacol Soc; 1979; 22():31-5. PubMed ID: 574646
    [No Abstract]   [Full Text] [Related]  

  • 14. Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
    Costall B; Naylor RJ
    Eur J Pharmacol; 1974 Jun; 27(1):46-58. PubMed ID: 4604756
    [No Abstract]   [Full Text] [Related]  

  • 15. 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors.
    Hjorth S; Carlsson A; Wikström H; Lindberg P; Sanchez D; Hacksell U; Arvidsson LE; Svensson U; Nilsson JL
    Life Sci; 1981 Mar; 28(11):1225-38. PubMed ID: 6112651
    [No Abstract]   [Full Text] [Related]  

  • 16. Behavioural observations in Gunn rats.
    Izquierdo I; Zand R
    Psychopharmacology (Berl); 1978 Apr; 57(2):155-61. PubMed ID: 418449
    [No Abstract]   [Full Text] [Related]  

  • 17. Rating the behavioral effects of amphetamine.
    Ellinwood EH; Balster RL
    Eur J Pharmacol; 1974 Sep; 28(1):35-41. PubMed ID: 4473346
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced locomotor activity following amphetamine in mouse-killing rats.
    Salama AI; Goldberg ME
    Arch Int Pharmacodyn Ther; 1973 Jul; 204(1):162-9. PubMed ID: 4795753
    [No Abstract]   [Full Text] [Related]  

  • 19. Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra.
    Costall B; Naylor RJ; Owen RT
    Eur J Pharmacol; 1978 Mar; 48(1):29-36. PubMed ID: 25189
    [No Abstract]   [Full Text] [Related]  

  • 20. The behavioral effects of D-amphetamine are correlated with its effects on cAMP in different brain regions.
    Kennedy LA; Zigmond MJ
    Brain Res; 1979 May; 168(2):408-13. PubMed ID: 221074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.